XBiotech Inc. (XBIT) Rolls Off 40% Amid Negative Trend Vote on Marketing Application of Cancer-treating Antibody

XBiotech Inc. (NASDAQ:XBIT) rolled off 40.04% or $6.82 to $10.20 per share on April 21, after announcing that its marketing authorization application (MAA) related to its candidate antibody for treating colorectal cancer received a negative “trend” vote from the European Medicines Agency (EMA). “We are disappointed by the outcome of the meeting. We believe that the data speak in a clear and resounding voice to clinical relevance of a new antibody therapy in advanced colorectal cancer, XBiotech Inc. (NASDAQ:XBIT) President and CEO John Simard said.

A negative trend vote means it is unlikely that a positive Committee for Medicinal Products for Human Use (CHMP) opinion related to the company’s MAA will be attained at the formal decision vote scheduled in May, and that additional steps would need to be taken to potentially gain marketing approval.

“We believe that findings from our Phase III study show that we have developed an important endpoint and methodology to evaluate anti-cancer therapy in advanced stage disease and that our monoclonal antibody represents a breakthrough treatment in patients with advanced colorectal cancer,” Simard said in a press release.

We see XBIT shares trading at a very high volume versus its average volume today while its price per share is falling nearer to the lower end of its 52-week range.




What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

None of the 742 funds we track at Insider Monkey hold shares of XBiotech Inc. (NASDAQ:XBIT)

The Bottom Line

XBiotech Inc. (NASDAQ:XBIT) shares are down tremendously by 40% intraday after receiving a negative “trend” vote to its marketing application related to a candidate antibody to treat colorectal cancer. For further reading, here are 10 best cancer hospitals in the world.

Follow Xbiotech Inc. (NASDAQ:XBIT)